From Yahoo Finance: 2025-05-13 08:46:00

In a recent article, Insider Monkey listed the “10 Best Low Priced Biotech Stocks to Buy Now,” including 89bio, Inc. (NASDAQ: ETNB). Analysts discuss how tariffs and policy risks are affecting the biotech industry but note potential buying opportunities due to low valuations.

The estimated tariff rate on the biotech sector is around 50%, with a negative EPS impact of -4-5%. Despite challenges like sector-specific tariffs and most favored nations potentially dropping drug prices by 40-50%, many biotech stocks are down 20-30% and offer buying opportunities with attractive valuations.

89bio, Inc. (NASDAQ: ETNB) is a clinical-stage biopharmaceutical company developing innovative therapies for liver and cardiometabolic diseases. Analysts are bullish on the company due to its strong position in the sector, with pegozafermin showing promise as a best-in-class treatment. The stock ranks 9th on the list of best low priced biotech stocks.

Insider Monkey compiled a list of 50 low-priced biotech stocks and selected the top 10 with the highest number of hedge fund holders. The data was recorded on May 9, showing a focus on stocks where hedge funds are investing for potential market outperformance.

Hedge fund sentiment data suggests that imitating top stock picks of the best hedge funds can lead to market outperformance. 89bio, Inc. (NASDAQ: ETNB) ranks high on the list of low priced biotech stocks, but there are other AI stocks with potentially higher returns in a shorter time frame. Explore opportunities beyond ETNB for significant gains.

Read more: Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now